ZA200204987B - Necleic acid vaccination. - Google Patents

Necleic acid vaccination. Download PDF

Info

Publication number: ZA200204987B
Authority: ZA; South Africa
Prior art keywords: nucleic acid; vaccine construct; composition; acid vaccine; tumours
Prior art date: 1999-12-22

Application number

ZA200204987A

Other languages

English (en)

Inventor

James Scott Crowe

Jonathan Henry Ellis

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-22

Filing date

2002-06-20

Publication date

2003-09-22

2002-06-20 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2003-09-22 Publication of ZA200204987B publication Critical patent/ZA200204987B/en

Links

238000002255 vaccination Methods 0.000 title claims description 30
239000002253 acid Substances 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 claims description 95
102000004196 processed proteins & peptides Human genes 0.000 claims description 89
229920001184 polypeptide Polymers 0.000 claims description 82
108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 claims description 66
229940023146 nucleic acid vaccine Drugs 0.000 claims description 66
102100034256 Mucin-1 Human genes 0.000 claims description 65
101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 62
108091033319 polynucleotide Proteins 0.000 claims description 42
102000040430 polynucleotide Human genes 0.000 claims description 42
239000002157 polynucleotide Substances 0.000 claims description 42
235000001014 amino acid Nutrition 0.000 claims description 38
206010028980 Neoplasm Diseases 0.000 claims description 36
150000001413 amino acids Chemical class 0.000 claims description 35
230000013595 glycosylation Effects 0.000 claims description 35
238000006206 glycosylation reaction Methods 0.000 claims description 35
239000000178 monomer Substances 0.000 claims description 35
229940024606 amino acid Drugs 0.000 claims description 34
239000000203 mixture Substances 0.000 claims description 34
229960005486 vaccine Drugs 0.000 claims description 25
239000012634 fragment Substances 0.000 claims description 24
230000035772 mutation Effects 0.000 claims description 24
239000002773 nucleotide Substances 0.000 claims description 18
125000003729 nucleotide group Chemical group 0.000 claims description 18
238000000034 method Methods 0.000 claims description 17
241000124008 Mammalia Species 0.000 claims description 16
108090000623 proteins and genes Proteins 0.000 claims description 16
238000006467 substitution reaction Methods 0.000 claims description 9
101100346932 Mus musculus Muc1 gene Proteins 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 8
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 7
210000002919 epithelial cell Anatomy 0.000 claims description 7
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
239000004473 Threonine Substances 0.000 claims description 6
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
210000004962 mammalian cell Anatomy 0.000 claims description 6
241000700721 Hepatitis B virus Species 0.000 claims description 5
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
229960000310 isoleucine Drugs 0.000 claims description 5
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 5
229960004295 valine Drugs 0.000 claims description 5
239000004474 valine Substances 0.000 claims description 5
206010006187 Breast cancer Diseases 0.000 claims description 4
208000026310 Breast neoplasm Diseases 0.000 claims description 4
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
101000981773 Arabidopsis thaliana Transcription factor MYB34 Proteins 0.000 claims description 3
101000651887 Homo sapiens Neutral and basic amino acid transport protein rBAT Proteins 0.000 claims description 3
102100027341 Neutral and basic amino acid transport protein rBAT Human genes 0.000 claims description 3
108010055044 Tetanus Toxin Proteins 0.000 claims description 3
108010015780 Viral Core Proteins Proteins 0.000 claims description 3
125000000539 amino acid group Chemical group 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 3
229940118376 tetanus toxin Drugs 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims description 3
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical group OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
241000272201 Columbiformes Species 0.000 claims description 2
102000018832 Cytochromes Human genes 0.000 claims description 2
108010052832 Cytochromes Proteins 0.000 claims description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
108010052285 Membrane Proteins Proteins 0.000 claims description 2
108010058846 Ovalbumin Proteins 0.000 claims description 2
241000237988 Patellidae Species 0.000 claims description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
229960003767 alanine Drugs 0.000 claims description 2
235000004279 alanine Nutrition 0.000 claims description 2
230000004075 alteration Effects 0.000 claims description 2
229960001230 asparagine Drugs 0.000 claims description 2
235000009582 asparagine Nutrition 0.000 claims description 2
235000014705 isoleucine Nutrition 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
229940092253 ovalbumin Drugs 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
235000014393 valine Nutrition 0.000 claims description 2
239000000126 substance Substances 0.000 claims 8
230000000063 preceeding effect Effects 0.000 claims 5
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
108010024636 Glutathione Proteins 0.000 claims 1
102400000368 Surface protein Human genes 0.000 claims 1
229960003180 glutathione Drugs 0.000 claims 1
210000004027 cell Anatomy 0.000 description 37
239000013612 plasmid Substances 0.000 description 24
102000039446 nucleic acids Human genes 0.000 description 22
108020004707 nucleic acids Proteins 0.000 description 22
150000007523 nucleic acids Chemical class 0.000 description 22
108020004414 DNA Proteins 0.000 description 21
102000004169 proteins and genes Human genes 0.000 description 8
108091034117 Oligonucleotide Proteins 0.000 description 7
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
239000000872 buffer Substances 0.000 description 7
238000010367 cloning Methods 0.000 description 7
230000028993 immune response Effects 0.000 description 7
239000002245 particle Substances 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
210000004881 tumor cell Anatomy 0.000 description 7
125000003275 alpha amino acid group Chemical group 0.000 description 6
229920000136 polysorbate Polymers 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
108091028043 Nucleic acid sequence Proteins 0.000 description 5
230000004989 O-glycosylation Effects 0.000 description 5
239000000427 antigen Substances 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
239000011324 bead Substances 0.000 description 5
150000001720 carbohydrates Chemical group 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
239000010931 gold Substances 0.000 description 5
229910052737 gold Inorganic materials 0.000 description 5
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
101710132601 Capsid protein Proteins 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
108010008707 Mucin-1 Proteins 0.000 description 4
238000012408 PCR amplification Methods 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
239000013598 vector Substances 0.000 description 4
238000005406 washing Methods 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
-1 cells Substances 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000010276 construction Methods 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
230000004044 response Effects 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 2
238000011238 DNA vaccination Methods 0.000 description 2
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
101000934372 Homo sapiens Macrosialin Proteins 0.000 description 2
102100025136 Macrosialin Human genes 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000003491 array Methods 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
239000002502 liposome Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000000243 solution Substances 0.000 description 2
241000894007 species Species 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000001117 sulphuric acid Substances 0.000 description 2
235000011149 sulphuric acid Nutrition 0.000 description 2
239000003656 tris buffered saline Substances 0.000 description 2
101100394745 Bacillus subtilis (strain 168) hepT gene Proteins 0.000 description 1
108020000946 Bacterial DNA Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010001498 Galectin 1 Proteins 0.000 description 1
102100021736 Galectin-1 Human genes 0.000 description 1
102100024637 Galectin-10 Human genes 0.000 description 1
101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 1
101001011021 Gallus gallus Gallinacin-12 Proteins 0.000 description 1
206010071602 Genetic polymorphism Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
102100028085 Glycylpeptide N-tetradecanoyltransferase 1 Human genes 0.000 description 1
241000175212 Herpesvirales Species 0.000 description 1
101000578329 Homo sapiens Glycylpeptide N-tetradecanoyltransferase 1 Proteins 0.000 description 1
101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
101150114927 MUC1 gene Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
101100338762 Pedobacter heparinus (strain ATCC 13125 / DSM 2366 / CIP 104194 / JCM 7457 / NBRC 12017 / NCIMB 9290 / NRRL B-14731 / HIM 762-3) hepB gene Proteins 0.000 description 1
241000009328 Perro Species 0.000 description 1
101710182846 Polyhedrin Proteins 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
102100037204 Sal-like protein 1 Human genes 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
229920006355 Tefzel Polymers 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000000137 annealing Methods 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
210000001106 artificial yeast chromosome Anatomy 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000012620 biological material Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
210000005220 cytoplasmic tail Anatomy 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000029087 digestion Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
QHSJIZLJUFMIFP-UHFFFAOYSA-N ethene;1,1,2,2-tetrafluoroethene Chemical compound C=C.FC(F)=C(F)F QHSJIZLJUFMIFP-UHFFFAOYSA-N 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
101150100470 frc gene Proteins 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003999 initiator Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
239000003049 inorganic solvent Substances 0.000 description 1
229910001867 inorganic solvent Inorganic materials 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
229940065638 intron a Drugs 0.000 description 1
230000009191 jumping Effects 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000010309 neoplastic transformation Effects 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229940023041 peptide vaccine Drugs 0.000 description 1
230000003094 perturbing effect Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
229960005190 phenylalanine Drugs 0.000 description 1
235000008729 phenylalanine Nutrition 0.000 description 1
238000013492 plasmid preparation Methods 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
ZDWVWKDAWBGPDN-UHFFFAOYSA-O propidium Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 ZDWVWKDAWBGPDN-UHFFFAOYSA-O 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002363 skeletal muscle cell Anatomy 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
108010044241 tetanus toxin fragment C Proteins 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)

ZA200204987A 1999-12-22 2002-06-20 Necleic acid vaccination. ZA200204987B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9930359.6A GB9930359D0 (en)	1999-12-22	1999-12-22	Novel polypeptides

Publications (1)

Publication Number	Publication Date
ZA200204987B true ZA200204987B (en)	2003-09-22

Family

ID=10866857

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200204987A ZA200204987B (en)	1999-12-22	2002-06-20	Necleic acid vaccination.

Country Status (21)

Country	Link
US (2)	US20030133909A1 (pt)
EP (1)	EP1240317B1 (pt)
JP (1)	JP2003517845A (pt)
KR (1)	KR20020073149A (pt)
CN (1)	CN1434862A (pt)
AT (1)	ATE355365T1 (pt)
AU (1)	AU2204901A (pt)
BR (1)	BR0016672A (pt)
CA (1)	CA2395208A1 (pt)
CZ (1)	CZ20022192A3 (pt)
DE (1)	DE60033690T2 (pt)
ES (1)	ES2282156T3 (pt)
GB (1)	GB9930359D0 (pt)
HU (1)	HUP0203848A3 (pt)
IL (1)	IL150285A0 (pt)
MX (1)	MXPA02006313A (pt)
NO (1)	NO20023010L (pt)
NZ (1)	NZ519732A (pt)
PL (1)	PL356697A1 (pt)
WO (1)	WO2001046228A2 (pt)
ZA (1)	ZA200204987B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0212046D0 (en) *	2002-05-24	2002-07-03	Glaxo Group Ltd	Vaccines
GB0212036D0 (en) *	2002-05-24	2002-07-03	Glaxo Group Ltd	Vaccines
GB0304634D0 (en) *	2003-02-28	2003-04-02	Glaxo Group Ltd	Vaccines
GB0321615D0 (en) *	2003-09-15	2003-10-15	Glaxo Group Ltd	Improvements in vaccination
EP3405212B1 (en)	2016-01-19	2020-07-08	Pfizer Inc	Cancer vaccines
CN106086050B (zh) *	2016-06-28	2020-01-07	中国人民解放军第二军医大学	携带muc1肿瘤抗原表位pdtrp的嵌合型病毒样颗粒及在胰腺癌中的应用
CA3070468A1 (en)	2017-09-01	2019-03-07	Dana-Farber Cancer Institute, Inc.	Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
AU2020231218A1 (en)	2019-03-06	2021-09-16	Dana-Farber Cancer Institute, Inc.	T cell receptors specific to B-cell maturation antigen for treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5695766A (en) *	1992-10-30	1997-12-09	Iowa State University Research Foundation	Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
US5744144A (en) *	1993-07-30	1998-04-28	University Of Pittsburgh University Patent Committee Policy And Procedures	Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AUPM322393A0 (en) *	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
DE19516673A1 (de) *	1995-04-28	1996-10-31	Gabriele Dr Pecher	Vakzine gegen Tumorerkrankungen
AUPN568095A0 (en) *	1995-09-27	1995-10-26	Austin Research Institute, The	Anti-Galalpha(1,3)Gal antibody binding peptides
AU734253B2 (en) *	1996-03-20	2001-06-07	Sloan-Kettering Institute For Cancer Research	Conjugated mucin peptide vaccines
US5744177A (en) *	1996-06-11	1998-04-28	Lin; Rong-Teng	Injection molding assembly

1999
- 1999-12-22 GB GBGB9930359.6A patent/GB9930359D0/en not_active Ceased
2000
- 2000-12-20 MX MXPA02006313A patent/MXPA02006313A/es unknown
- 2000-12-20 WO PCT/GB2000/004906 patent/WO2001046228A2/en active IP Right Grant
- 2000-12-20 CZ CZ20022192A patent/CZ20022192A3/cs unknown
- 2000-12-20 EP EP00985646A patent/EP1240317B1/en not_active Expired - Lifetime
- 2000-12-20 AU AU22049/01A patent/AU2204901A/en not_active Abandoned
- 2000-12-20 BR BR0016672-3A patent/BR0016672A/pt not_active IP Right Cessation
- 2000-12-20 DE DE60033690T patent/DE60033690T2/de not_active Expired - Lifetime
- 2000-12-20 CA CA002395208A patent/CA2395208A1/en not_active Abandoned
- 2000-12-20 US US10/168,873 patent/US20030133909A1/en not_active Abandoned
- 2000-12-20 PL PL00356697A patent/PL356697A1/xx not_active Application Discontinuation
- 2000-12-20 IL IL15028500A patent/IL150285A0/xx unknown
- 2000-12-20 JP JP2001547137A patent/JP2003517845A/ja active Pending
- 2000-12-20 HU HU0203848A patent/HUP0203848A3/hu unknown
- 2000-12-20 ES ES00985646T patent/ES2282156T3/es not_active Expired - Lifetime
- 2000-12-20 CN CN00819076A patent/CN1434862A/zh active Pending
- 2000-12-20 NZ NZ519732A patent/NZ519732A/en unknown
- 2000-12-20 KR KR1020027008063A patent/KR20020073149A/ko not_active Application Discontinuation
- 2000-12-20 AT AT00985646T patent/ATE355365T1/de not_active IP Right Cessation
2002
- 2002-06-20 ZA ZA200204987A patent/ZA200204987B/en unknown
- 2002-06-21 NO NO20023010A patent/NO20023010L/no not_active Application Discontinuation
2006
- 2006-11-02 US US11/555,793 patent/US20070269451A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60033690T2 (de)	2007-11-08
NZ519732A (en)	2004-03-26
WO2001046228A3 (en)	2002-01-17
EP1240317A2 (en)	2002-09-18
HUP0203848A3 (en)	2004-07-28
NO20023010L (no)	2002-08-06
MXPA02006313A (es)	2002-11-29
KR20020073149A (ko)	2002-09-19
PL356697A1 (en)	2004-06-28
US20070269451A1 (en)	2007-11-22
JP2003517845A (ja)	2003-06-03
CN1434862A (zh)	2003-08-06
BR0016672A (pt)	2002-10-08
ATE355365T1 (de)	2006-03-15
NO20023010D0 (no)	2002-06-21
HUP0203848A2 (hu)	2003-03-28
DE60033690D1 (de)	2007-04-12
EP1240317B1 (en)	2007-02-28
ES2282156T3 (es)	2007-10-16
WO2001046228A2 (en)	2001-06-28
CZ20022192A3 (cs)	2002-11-13
GB9930359D0 (en)	2000-02-09
CA2395208A1 (en)	2001-06-28
AU2204901A (en)	2001-07-03
US20030133909A1 (en)	2003-07-17
IL150285A0 (en)	2002-12-01

Publication	Publication Date	Title
US7446185B2 (en)	2008-11-04	Her2/neu target antigen and use of same to stimulate an immune response
JP3581366B2 (ja)	2004-10-27	免疫原のリソソーム標的
KR100922809B1 (ko)	2009-10-21	면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
US20070269451A1 (en)	2007-11-22	Nucleic Acid Vaccination
JP2005341969A (ja)	2005-12-15	小胞体シグナル配列ペプチドと少なくとも１個の他のペプチドをエンコードする核酸配列を含有する免疫原性キメラ、及びこのキメラのワクチン及び疾患の治療における使用
BRPI0611794A2 (pt)	2010-09-28	métodos e composições para induzir respostas imunes multivalentes contra epìtopos dominantes e subdominantes, expressos em células de cáncer e estroma tumoral
JP5148116B2 (ja)	2013-02-20	癌胎児性抗原融合タンパク質及びその使用
JP2002517249A (ja)	2002-06-18	抗原およびＥＢＶＧｐ３５０／２２０の受容体の同時刺激によるＢ細胞活性化および免疫グロブリン分泌の増強
US12234261B2 (en)	2025-02-25	Hepatitis B vaccines and uses of the same
JP2005526520A (ja)	2005-09-08	Ｖｎｔｒ反復ユニットの数が減少したｍｕｃ−１抗原
CA2529058A1 (en)	2005-01-13	Increased t-cell tumor infiltration by mutant light
JP2007505601A (ja)	2007-03-15	ワクチン
JP2005526511A (ja)	2005-09-08	ワクチン
KR102297440B1 (ko)	2021-09-02	표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도
WO2024222886A1 (zh)	2024-10-31	一种针对MICA/B靶点的mRNA肿瘤疫苗